Our Science
Targeting Brain Endothelial Biology
The stability and permeability of the BBB is modulated by brain endothelial cells that control tight junction integrity, immune signaling and vascular permeability
We are developing antibody-based therapeutics designed to restore endothelial stability and restore BBB function under disease conditions.
Restoring the Blood–Brain Barrier
A New Therapeutic Strategy for Neurological Disease
Phragma’s lead program is focused on restoring BBB integrity by correcting brain endothelial dysfunction.
The approach is based on monoclonal antibodies designed to:
- strengthen endothelial tight junctions
- reduce pathological vascular leakage
- limit immune cell infiltration into the brain
This strategy addresses an upstream driver of neurological disease rather than downstream symptoms.
Primary Indication: Multiple Sclerosis
In multiple sclerosis, breakdown of the blood–brain barrier allows immune cells to enter the brain and attack myelin and neurons.
Although anti-inflammatory therapies exist, disease progression often continues, suggesting that upstream mechanisms remain insufficiently controlled.
By restoring BBB integrity, Phragma aims to target a fundamental mechanism contributing to disease progression.
Broader Indication Potential
BBB dysfunction also plays a role in numerous neurological conditions, including:
- Alzheimer’s disease
- Vascular dementia
- Cerebral amyloid angiopathy
- Stroke
- Traumatic brain injury
This creates the potential for broad therapeutic impact across CNS disorders.
Antibody-Mediated BBB Opening
Unlocking Payload-Agnostic CNS Drug Delivery
One of the biggest challenges in neurology is that most therapeutics cannot cross the blood–brain barrier.
Approximately 98% of small molecules and nearly 100% of large molecules fail to penetrate the BBB effectively.
A New Platform for CNS Therapeutics
Phragma is developing monoclonal antibodies capable of transiently and selectively modulating BBB tight junctions, allowing therapeutics to enter the brain following standard systemic administration.
This approach could enable payload agnostic delivery of small molecules and biologics to the central nervous system.
Copyright © 2026 Phragma Therapeutics - All Rights Reserved.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.